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Abstract 
Background: Monocytes, the primary myeloid cell-type in peripheral blood, are resistant to HIV-1 infection as a 
result of the lentiviral restriction factor SAMHD1. Toll-like receptors recognize microbial pathogen components, 
inducing the expression of antiviral host proteins and proinflammatory cytokines. TLR agonists that mimic micro-
bial ligands have been found to have activity against HIV-1 in macrophages. The induction of restriction factors 
in monocytes by TLR agonist activation has not been well studied. To analyze restriction factor induction by TLR 
activation in monocytes, we used the imidazoquinoline TLR7/8 agonist R848 and infected with HIV-1 reporter 
virus that contained packaged viral accessory protein Vpx, which allows the virus to escape SAMHD1-mediated 
restriction. 
Results: R848 prevented the replication of Vpx-containing HIV-1 and HIV-2 in peripheral blood mononuclear cells 
and monocytes. The block was post-entry but prior to reverse transcription of the viral genomic RNA. The restriction 
was associated with destabilization of the genomic RNA molecules of the in-coming virus particle. R848 treatment of 
activated T cells did not protect them from infection but treated monocytes produced high levels of proinflammatory 
cytokines, including type-I IFN that protected bystander activated T cells from infection.
Conclusion: The activation of TLR7/8 induces two independent restrictions to HIV-1 replication in monocytes: a 
cell-intrinsic block that acts post-entry to prevent reverse transcription; and a cell-extrinsic block, in which monocytes 
produce high levels of proinflammatory cytokines (primarily type-I IFN) that protects bystander monocytes and T 
lymphocytes. The cell-intrinsic block may result from the induction of a novel restriction factor, which can be termed 
Lv5 and acts by destabilizing the in-coming viral genomic RNA, either by the induction of a host ribonuclease or by 
disrupting the viral capsid. TLR agonists are being developed for therapeutic use to diminish the size of the latent pro-
virus reservoir in HIV-1 infected individuals. Such drugs may both induce latent provirus expression and restrict virus 
replication during treatment.
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Background
Toll-like receptors (TLR) are membrane-associated pat-
tern recognition receptors (PRRs) expressed in myeloid 
cells that serve as a line of first defense against bacte-
rial and viral pathogens. The TLRs are activated by 
pathogen-associated molecular patterns (PAMPs) that 
trigger a signal transduction to activate innate and 
adaptive immune responses, resulting in the release of 
proinflammatory cytokines, chemokine and type-I inter-
ferons (IFN). The cytokines released induce the expres-
sion of an array of antiviral genes that inhibit virus 
replication through various mechanisms and cause T 
cells to increase expression of co-stimulatory proteins. 
PAMPs detected by the 10 TLRs encoded in the human 
genome include single-stranded RNA (TLR7 and 8), 
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double-stranded RNA (TLR3) and double-stranded DNA 
(TLR9) [1–3].
Because of their ability to induce innate and adaptive 
responses, TLR agonists have been explored as antivi-
ral therapeutic agents. Agonists for TLR3, TLR4, TLR7, 
TLR8 and TLR9 have been used in nonhuman primate 
models for dengue virus and in murine models for her-
pes simplex virus-type-1 and -2 where they have been 
found to attenuate viral symptoms and replication [4–6]. 
Several TLR agonists inhibit the replication of HIV-1 in 
lymphocytes, monocytes and monocyte-derived mac-
rophages (MDM). The imidazoquinoline TLR7/8 ago-
nists R848 (resiquimod) and gardiquimod were found 
to inhibit HIV-1 replication in MDMs by inducing solu-
ble antiviral factors and in the case of gardiquimod, by 
acting as a nucleoside reverse transcriptase inhibitor 
[7, 8]. In monocytes isolated from HIV-infected indi-
viduals, R848-treatment reduced viral RNA in the cul-
ture supernatants [9]. In addition, the TLR9 agonist 
ODN2395 induces the restriction factors  APOBEC3G 
and SAMHD1 [10]. Clinically, TLR7 and 8 agonists are 
used to treat inflammatory disorders and viral infections. 
R848 is used to treat psoriasis and HSV-2 induced geni-
tal lesions and the related imidazoquinoline, imiquimod, 
is used to treat human papilloma virus genital warts [11, 
12].
 In myeloid cells in culture, HIV-1 has been reported 
to be  sensed by PRRs including the TLRs [13]. In plas-
macytoid dendritic cells (pDC), HIV-1 virion genomic 
RNA was found to activate endosomal TLR 7/8 and TLR9 
resulting the production of high levels of type-I IFN   
[14–16]. In addition,  HIV-1 RNA  activates TLR8, lead-
ing to inflammasome activation and the release of IL-1β 
and IL-18 [17, 18]. Oligonucleotides with HIV-1 RNA 
derived sequences stimulate TLR7 and TLR8 in pDCs, 
monocyte-derived DCs (MDDC), MDMs and monocytes 
[19, 20]. In addition, HIV-1 virions and TLR7/8 agonists 
both stimulate monocytes to produce IP-10  [21]. The 
HIV-1 envelope glycoprotein activates cell surface TLR2 
and TLR4 [22, 23]. While these data are based upon stud-
ies of cells in culture, the role of innate sensing in HIV-1 
replication and pathogenesis in  vivo remains to be 
determined.
Monocytes, the myeloid cell-type that is most prevalent 
in the blood, are largely resistant to HIV-1 [24] as a result 
of SAMHD1, a phosphohydrolase that depletes the intra-
cellular pool of dNTPs, preventing reverse transcription 
[25–27]. HIV-2 and the SIV of rhesus macaques encode 
Vpx, a virion-packaged accessory protein that induces 
the proteasomal degradation of SAMHD1 in the nucleus, 
allowing the viruses to evade the restriction and repli-
cate in monocytes, macrophages and DC [28–34]. HIV-1 
lacks Vpx accounting for the inability of the virus to rep-
licate to high titer on monocytes, macrophages and DC. 
Vpx is packaged in HIV-2 and SIV virions by an amino 
acid motif located at amino acids 17–26 in the P6 region 
of the Gag polyprotein precursor that is absent in HIV-1 
[35]. The virus can be engineered to package Vpx by plac-
ing the SIV Vpx packaging motif in Gag P6, resulting in a 
two order of magnitude increase in infectivity of myeloid 
cells [36].
In this study, we investigated the effect of the TLR7/8 
agonist R848 on HIV-1 replication in primary myeloid 
and lymphoid cells using Vpx-containing HIV-1 and 
HIV-2. The agonist potently restricted the replication of 
both viruses in monocytes. The restriction was not medi-
ated by SAMHD1 or other known restriction factors 
including APOBEC3A. The restriction  was post-entry, 
preventing reverse transcription and was independent 
of type-I IFN signaling. The restriction was associated 
with destabilization of the virion genomic RNA of the 
in-coming virus suggesting a role for a restriction factor 
with ribonuclease activity or with an ability to interfere 
with capsid stability. In addition to inducing a novel IFN-
independent restriction factor, R848 caused monocytes 
to release proinflammatory cytokines that protected 




293T and HL116 cells were cultured in Dulbecco’s modi-
fied Eagle medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and penicillin/streptomycin. PBMC 
were prepared by Ficoll density gradient centrifugation 
of blood from anonymous donors provided by the New 
York Blood Center. The monocytes were purified by plas-
tic adherence and cultured in RPMI containing 10  mM 
HEPES, 24  µg/ml gentamicin, and 5% heat inactivated 
pooled human serum (PHS). Monocyte purity was deter-
mined by flow cytometry using a PE-conjugated anti-
CD14 antibody (BD biosciences). MDDC were prepared 
by culturing the monocytes for 5  days in medium con-
taining 110 U/mL GM-CSF and 300 U/mL IL-4, replac-
ing the cytokines every 2 days. MDM were prepared by 
culturing the monocytes for 5 days in medium contain-
ing 50  ng/ml GM-CSF. CD4+ T cells were isolated by 
negative selection of the PBMCs on EasySep human 
CD4+ T cell magnetic beads (Stem Cell Technologies). 
The CD4+ T cells were activated for 2  days with CD3/
CD28 beads (LifeTechnologies) using 2 cells per bead 
and cultured in RPMI containing 5% PHS, 1 mM HEPES, 
2  mM  l-glutamine, MEM non-essential amino acids, 
penicillin/streptomycin and 100 U/mL recombinant IL-2. 
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CD4+ T cell purity was evaluated by staining with Alexa 
700-anti-CD3 and allophycocyanin-anti-CD4 monoclo-
nal antibodies (BioLegend) and analyzed by flow cytom-
etry. BMDCs were prepared by flushing the marrow cells 
from C57BL/6 SAMHD1 knock-out mouse femurs. The 
red blood cells were removed with ammonium chloride 
lysing buffer and the cells were cultured for 6–8 days in 
RPMI supplemented with 1 mM sodium pyruvate, 2 mM 
l-glutamine and 10 ng/ml murine GM-CSF (Peprotech). 
R848 to stimulate TLR7/8 was obtained from Invivogen 
and diluted to the indicated final concentration(s) in the 
respective culture medium.
Plasmids
HIV-2 GFP reporter virus plasmids pHIV2.GFPΔVpr 
and pHIV2.GFPΔVprΔVpx were constructed by subclon-
ing the BsmB-I to Avr-II fragment of pHIV2.E-.GFP that 
contains the vpx/vpr genes. Translational stop codons 
were introduced into vpx at amino acids 22 and 24 with-
out altering the overlapping amino acids encoded by 
vif. The vpr translational initiation codon was removed 
by mutation to ATC and amino acids 2, 3 and 4 were 
changed to translational termination codons by overlap-
ping PCR (TAA TAA TGA). The amplicon was digested 
with BsmBI and Avr-II and cloned back into pHIV2.E-.
GFP. Plasmid sequences were confirmed by nucleotide 
sequence analysis.
Viruses
Reporter viruses were prepared by calcium phosphate 
transfection of 293T cells. VSV-G pseudotyped HIV-1 
luciferase reporter virus was produced by co-transfecting 
with pNL.luc3.p6* E-R- [36], pVSV-G [37] and pcVpx 
[36] or pcDNA6 at a mass ratio of 10:1:1. Viruses bearing 
CCR5-tropic HIV-1 envelope glycoprotein from trans-
mitted founder virus WEAUd15.410.5017 [38] were pro-
duced by transfection with a mass ratio of 6:6:1. HIV-1 
GFP reporter virus was produced by cotransfection with 
pHIV1.CMV.GFP.p6* E-R- [39]. HIV-2 GFP reporter 
virus was produced by cotransfection with pHIV2.GFP 
E-R- or pHIV2.GFP E-R-X- and pVSV-G at a mass ratio 
of 10:1. Viruses were harvested 48 h post transfection, fil-
tered through a 0.45 µm filter and concentrated by ultra-
centrifugation for 90 min at 4 °C at 30,000 rpm through 
a 20% sucrose cushion. The viruses were resuspended in 
RPMI containing 5% PHS, frozen at −80 °C and tittered 
on 293T cells.
qPCR quantification of HIV‑1 reverse transcripts
Monocytes were isolated by plastic adherence from 
1.5 ×  107 PBMC plated in 6-well plates. The cells were 
treated with 10 μM R848 or 100 U/mL IFNα. After 24 h, 
the cells were infected with benzonase-treated Vpx-con-
taining HIV-1 luciferase reporter virus (1.5  ×  107 cps) 
in the presence or absence of 10 μM nevirapine. At 40 h 
post-infection, DNA was isolated and 250  ng  were ana-
lyzed by qRT-PCR using SYBR green (Molecular Probes) 
with primers that amplified early or late HIV-1 reverse 
transcripts (early RT: fw 5′-GTG CCC GTC TGT TGT 
GTG AC and rev 5′-GGC GCC ACT GCT AGA GAT 
TT; late RT: fw 5′-TGT GTG CCC GTC TGT TGT GT 
and rev 5′-GAG TCC TGC GTC GAG AGA GC) [40]. 
The data were normalized to a standard curve generated 
with proviral plasmid DNA serially diluted in 293T cell 
genomic DNA.
Reverse transcriptase qRT‑PCR mRNA quantification
RNA was isolated from 5.0 × 107 monocytes using Tri-
zol and treated with RNase-free DNase I (Roche). cDNA 
was synthesized using an oligo-dT primer and Transcrip-
tor RT (Roche). cDNA corresponding to 50  ng of RNA 
was analyzed by qRT-PCR using SYBR green to quantify 
mRNA transcripts for p21 (fw 5′-GCA GAC CAG CAT 
GAC AGA TTT and rev 5′-GGA TTA GGG CTT CCT 
CTT GGA), RRM2 (fw 5′-AAG AAG AAG GCA GAC 
TGG GC and rev 5′-CCA GGC ATC AGT CCT CGT 
TT) IL-1β (fw 5′-ATG ATG GCT TAT TAC AGT GGC 
AA and rev 5′-GTC GGA GAT TCG TAG CTG GA-) and 
GAPDH (fw 5′-TGG AAG GAC TCA TGA CCA CAG 
and rev 5′-CAG TCT TCT GGG TGG CAG TGA). Reac-
tions without RT were included to control for genomic 
DNA contamination. The ΔΔCT relative to GAPDH in 
the untreated samples was set to 1.
βlam fusion assay
Virions containing Vpr-β-lactamase fusion protein (Vpr.
BlaM) were produced using Vpr.BlaM expression vec-
tor pMM310. Monocytes (1.0  ×  106) were treated for 
24  h with R848 and then exposed to the virions. After 
5  h, the cells were loaded with coumarin cephalosporin 
fluorescein (CCF2) (ThermoFisher) and analyzed by flow 
cytometry.
SAMHD1 degradation
Monocytes (5.0 × 106) were incubated with 10 μM R848 
or 100 U/mL IFNα for 24 h and then infected with Vpx-
containing HIV-1 (5.0 × 106 cps). The next day, the cells 
were lysed in buffer containing 50 mM HEPES, 150 mM 
KCl, 2.0 mM EDTA, 0.5% NP-40 and protease inhibitors. 
The cell lysates were analyzed on an immunoblot probed 
with anti-SAMHD1 mAb (Origene) and anti-GAPDH 
mAb (Ambion) and horseradish peroxidase-goat anti-
mouse immunoglobulin (Pierce) second antibody. The 
signals were detected with Super Signal West Pico 
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(ThermoFisher) and quantified on an Odyssey FC imager 
(LI-COR).
Cell viability assays
Cell viability was determined by trypan blue stain-
ing, MTS assay (Promega) and flow cytometry with 
Pacific Blue fixable viability dye eflour450 (eBiosciences) 
staining.
Cytokine quantification
Monocytes were treated for 2  h with 1  μM R848 after 
which the drug was removed by extensive washing. After 
22 h, the supernatant was harvested and type-I IFN was 
quantified on HL116 IFN reporter cells [41] and the pro-
inflammatory cytokines were quantified by cytometric 
bead array (BD Biosciences).
RNA stability assay
Monocytes (2 × 107) in a 6-well plate were untreated or 
treated for 24 h with 1 μM R848. 10 μM Nevirapine was 
added and the cells were infected for 2 h at 16 C° by spin-
noculation at 2200  rpm in a table-top centrifuge with 
Vpx-containing HIV-1 (2 × 107 cpm luciferase activity). 
The cells were harvested 0.5, 1 and 3  h post-infection 
and RNA was prepared. The HIV-1 genomic RNA cop-
ies in 175 ng RNA was quantified by SYBR green reverse 
transcriptase qRT-PCR using primer pairs that ampli-
fied the reporter virus luciferase gene (luc3-fw3 5′-TGG 
GCG CGT TAT TTA TCG GA and luc3-rv3 5′-GCT 
GCG AAA TGC CCA TAC TG), the 5′ end of the viral 
RNA (5′-LTR-fw 5′-GCT CAA AGT AGT GTG TGC 
CC, 5′-LTR-rev 5′-CTC CTC TGG CTT TAC TTT CGC, 
and the 3-end of the viral RNA (3′-LTR-fw 5′-CGA GCT 
TGC TAC AAG GGA C and 3′-LTR-rv 5′-GCT TAA 
GCA GTG GGT TCC C). Control reactions without 
RT were included to detect contaminating viral DNA. 
HIV genomic RNA was calculated as ΔΔCT relative to 
GAPDH mRNA.
Results
R848 induces a block to HIV‑1 infection of monocytes
The TLR7/8 agonist R848 has been found to induce a 
block to HIV-1 replication in monocytes and MDMs 
[7, 8, 10]. To further investigate the mechanism by 
which the drug interferes with HIV-1 replication we 
used a VSV-G-pseudotyped reporter virus engineered 
to package the SIVmac accessory protein Vpx [36]. Vpx 
degrades SAMHD1, overcoming the block to HIV-1 
infection of resting T cells and primary monocytes [33, 
34, 42, 43] allowing us to test how well the drug blocks 
infection and to investigate its antiviral mechanism. To 
determine which cell-types are protected by the ago-
nist, we treated PBMCs from healthy donors for 24  h 
with R848 and then infected them with Vpx-contain-
ing, HIV-1 luciferase reporter virus. For comparison, 
we treated the PBMCs with type-I IFN, an inducer of 
multiple antiviral pathways. To ensure that the activ-
ity measured was due to bona fide infection, control 
PBMCs were treated with the reverse transcriptase 
inhibitor nevirapine. Infectivity was measured by 
intracellular luciferase assay 72  h post-infection. The 
results showed that R848 potently blocked infection of 
the PBMCs, with 10  μM drug reducing infectivity 20- 
to 175-fold in 18 different donors (Fig.  1a and Addi-
tional file 1). This effect was at least as strong as a high 
dose of  IFNα. The infectability of PBMCs was highly 
dependent upon Vpx in the virions which increased the 
infection by 200-fold.
PBMCs are a mixture of resting lymphocytes and 
myeloid cell-types. Because Vpx facilitates the infection 
of monocytes and resting lymphocytes, it was unclear 
which cell-types in the PBMC population had become 
infected. To determine the cell-types that had been 
infected by Vpx-containing virus, we infected PBMCs 
with VSV-G pseudotyped, Vpx-containing HIV-1 GFP 
reporter virus and after 3 days, analyzed the cells by flow 
cytometry to determine the numbers of infected CD4+ 
T cells (CD4+/CD3+/CD14−) and monocytes (CD4−/
CD3−/CD14+). The results showed that the infec-
tion was Vpx-dependent and that it was the monocytes 
(CD14+) that had been infected (Fig.  1b). Despite the 
packaged Vpx, the resting CD4+ T cells were not appre-
ciably infected. We concluded that Vpx allowed for effi-
cient infection of the monocytes and that R848 blocked 
their infection.
To confirm that it was the monocytes that had been 
protected by R848 and to test whether this was a direct 
effect or whether it was mediated by another cell-type 
in the culture such as pDCs that had released a soluble 
inhibitor, we tested the effect of R848 on monocytes puri-
fied from the PBMCs of three healthy donors. The results 
showed that the drug protected the monocytes from 
infection (Fig. 1c). Further analysis of monocytes purified 
from 15 donor PBMCs showed that the drug was active 
on monocytes from all of the donors, reducing the num-
ber of infected cells 15- to 100-fold (Fig. 1d). The effect of 
the drug was not the result of toxicity as an analysis using 
three cell viability assays showed no effect on cells treated 
with R848 at concentrations that induced the block to 
infection (Additional file 2).
The experiments above used virions engineered to 
package Vpx. To determine whether R848 would block 
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the infection of monocytes by a virus for which these 
cells are a natural target and that naturally encodes Vpx, 
we tested its effect on infection by HIV-2. We infected 
monocytes with wild-type or Vpx-mutated HIV-2 GFP 
reporter virus. For comparison, the monocytes were 
infected with Vpx-containing or lacking HIV-1 GFP 
reporter virus and after 3  days analyzed infectivity  by 
flow cytometry. The results showed that infection of 
the monocytes by HIV-2 was dependent upon Vpx and 
that the infection was blocked by R848 (Fig.  1e, g). The 
effect on HIV-2 was somewhat more pronounced than 
on HIV-1 (Fig.  1f, h), perhaps because of the decreased 
infectivity of this virus. For both viruses, the drug 
decreased the number of GFP+ cells and not the mean 
fluorescence intensity, indicating that the drug prevented 
infection rather than decreased LTR-driven transcription 
of the GFP reporter. The findings demonstrate that R848 
induces a block to HIV-2 in monocytes, a cell-type that is 
a natural target of the virus.
The R848‑induced restriction is SAMHD1‑independent
SAMHD1 is expressed in monocytes where it acts as 
the major block to infection, as is clear from the ability 
of Vpx-containing viruses to efficiently infect these cells. 
The fact that R848 blocked the infection of monocytes 
with Vpx-containing virus suggests that SAMHD1 was 
not the mechanism by which R848 protected these cells 
from infection. However, this finding does not defini-
tively rule-out a role for SAMHD1-mediated restric-
tion, as R848 could prevent SAMHD1 degradation by 
Vpx or activate its phosphohydrolase activity. To test 
whether the R848-induced block to infection was medi-
ated by SAMHD1, we treated monocytes with the drug 
for 24  h and then infected them with Vpx-containing 
HIV-1 or control supernatant. The next day we quanti-
fied SAMHD1 protein by immunoblot analysis. R848 
did not affect the amount of SAMHD1 nor did it inter-
fere with the ability of Vpx to induce SAMHD1 degra-
dation (Fig.  2a). To determine whether R848 inhibition 




Fig. 1 R848 prevents the infection of monocytes by HIV-1 and HIV-2. a Non-stimulated PBMCs from three donors (one bar represents one donor) 
were untreated (−) or treated for 24 h with 10 µM R848 (blue) or 100 U/mL IFNα and then infected with HIV-1 luciferase reporter virus lacking (HIV1) 
or containing packaged Vpx (HIV1 X+). Uninfected (mock) or nevirapine (NVP) treated cells were included as controls. After 72 h luciferase activity 
was measured. b Non-stimulated PBMCs were infected with HIV-1 GFP reporter virus containing (HIV1 X+) or lacking (HIV1) Vpx. After 72 h the 
cells were stained with Alexa700-anti-CD4, APC-anti-CD3 and PE-anti-CD14 antibodies and analyzed by flow cytometry. c Monocytes from three 
donors were treated with R848 (blue) and infected with reporter virus as in (a). d Monocytes from 15 healthy donors were treated (blue squares) or 
untreated (black dots) with 10 µM R848 and then infected with Vpx-containing luciferase reporter virus (***p = 0.0004). e, f Monocytes were treated 
or untreated with R848 (−) for 24 h and then infected with wild-type or delta Vpx HIV-2 GFP reporter virus (HIV2) (e) or Vpx-containing (HIV1 X+) 
or lacking (HIV1) HIV-1 GFP reporter virus (f). Uninfected cells serve as control (mock). After 72 h, the cells were analyzed by flow cytometry. g Sum-
mary of 3 healthy donors infected as in e; *p = 0.0175. h Summary of 3 healthy donors infected as in (f); ***p = 0.0008
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was dependent on SAMHD1, we tested whether the 
drug blocked the infection of SAMHD1 knock-out 
mouse bone marrow derived DCs (BMDC). R848 treat-
ment caused a 100-fold block to infection of the knock-
out BMDCs by HIV-1 reporter virus, an effect that was 
similar to that in human monocytes (Fig.  2b). The drug 
had no effect on the viability of the BMDCs (Additional 
file 2).
R848 acts rapidly and is active against HIV‑1 bearing a 
primary CCR5‑using HIV‑1 envelope glycoprotein
To characterize the antiviral activity of R848, we tested 
whether the effect could be saturated by increasing the 
MOI, as is the case for some of the other restriction fac-
tors by treating monocytes with 1 or 10  μM R848 and 
infecting with increasing MOI. The results showed that 
the degree of inhibition remained constant regardless 
of the MOI (Fig. 3a). Similar results were obtained with 
an analysis of two additional donors (Additional file  3). 
A dose–response curve for the drug on monocytes 
from three donors showed an average IC50 of 0.05  μM 
(Fig.  3b). The drug was most active when added 24  h 
prior to infection, causing a 100-fold reduction of HIV-1 
reporter virus  infection. When added at the same time 
as the virus, the block was still active, causing a 6.5- and 
33-fold inhibition of infection in the two donors tested 
(Fig.  3c). To show that the restriction is not limited to 
VSV-G pseudotyped virus, we tested whether R848 
would inhibit infection by reporter virus pseudotyped 
with  a transmitted-founder envelope glycoprotein [38]. 
The results showed that virus pseudotyped by an HIV-1 
envelope glycoprotein was senstive to the drug, resulting 
in a 2.5- to 8.5-fold reduction in the number of infected 
monocytes (Fig.  3d). While the reduction in infectivity 
was not as pronounced as that of the VSV-G pseudotype, 
this most likely results from the reduced infectivity of the 
reporter virus bearing HIV-1 envelope glycoprotein. The 
effect of which is a reduced dynamic range of the analy-
sis, and does not reflect an ability of the virus to evade 
the R848-induced restriction. Taken together, R848 is 
a potent inhibitor of monocyte infection by HIV-1 that 
acts regardless of the route of entry and is not saturated 
by a high dose of virus.
The block to infection is post‑entry at reverse transcription
To determine the step at which R848 blocks HIV-1 infec-
tion, we tested whether the drug prevents envelope gly-
coprotein-mediated fusion using the Vpr.βlaM fusion 
assay [44]. The results showed that R848 did not affect 
VSV-G-mediated fusion on monocytes (Fig. 4a). To test 
the effect of the drug on reverse transcription, we treated 
monocytes with R848, IFNα or nevirapine and then 
infected them with Vpx-containing HIV-1. After 40  h, 
we quantified the early and late HIV-1 reverse transcripts 
by qRT-PCR. The results showed that R848 decreased 
the copy number of early reverse transcripts 2- to 100-
fold (Fig. 4b) and the number of late reverse transcripts 
10- to 200-fold (Fig. 4c). IFNα had no effect on the num-
ber of viral DNA copies, consistent with its post-reverse 
transcription effect. The nevirapine control confirmed 
that the DNA copies were the result of reverse transcrip-



















































b BMDC SAMHD1 (-/-)
Fig. 2 R848 induces a SAMHD1-independent block to infection of monocytes. a Monocytes from 2 healthy donors were treated for 24 h with 
10 µM R848 or 100 U/mL IFNα and then infected with Vpx-containing HIV-1 (HIV1 X+). After 24 h, lysates were prepared and SAMHD1 was quanti-
fied by immunoblot analysis with a GAPDH loading control. b BMDC from two SAMHD1 knock-out mice (one bar per mouse) were treated for 24 
h with (blue) or without 10 µM R848 and then infected with HIV-1 luciferase reporter virus (HIV1) in the presence or absence of Nevirapine (NVP). 
Luciferase activity was measured after 72 h
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transcription and that the effect differs from that of type-
I IFN.
We also considered the possibility that the antiviral 
activity was mediated by APOBEC3A, an antiviral host 
factor that has been proposed to restrict HIV-1 replica-
tion in monocytes [45, 46]. Immunoblot analysis showed 
that R848 did not induce the expression of APOBEC3A 
in monocytes (Additional file 4). We further considered 
the possibility that R848 acts on p21, which is thought 
to regulate the intracellular dNTP concentration by 
decreasing the expression of ribonucleotide reduc-
tase [47] or by regulating SAMHD1 activity [48]. How-
ever, qRT-PCR analysis showed R848 did not affect the 
abundance of p21 mRNA transcripts in monocytes and 
that it increased rather than decreased the number of 
RNR mRNA transcripts (Fig.  4d). Taken together, the 
findings demonstrate that the SAMHD1-independent 
block is post-entry at reverse transcription and is not 
mediated by APOBEC3A or p21 expression.
R848 destabilizes HIV‑1 virion genomic RNA
The effect on viral DNA copy number could result from a 
block to reverse transcriptase or from degradation of the 
viral genomic RNA template. To test for an effect of R848 
on viral genomic RNA stability, we treated monocytes 
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Fig. 3 R848 induces a potent and rapid block to infection with virus bearing a primary HIV-1 isolate envelope glycoprotein. a Monocytes were 
incubated with 1 µM (dark blue) or 10 µM (light blue) R848 for 24 h and then infected with increasing amounts of Vpx-containing HIV-1 luciferase 
reporter virus (0.1, 0.3, 1.0 and 3 × 106 cps). Uninfected (mock) and cells infected with virus lacking Vpx (HIV1) were included as controls. b Mono-
cytes from three donors were treated for 24 h with serial dilutions of R848 and then infected with Vpx-containing HIV-1 luciferase reporter virus. c 
Monocytes were untreated (−) or treated with 10 µM R848 24 h before infection (24 h, blue solid) or at the time of infection (0 h, blue dotted) with 
Vpx-containing or lacking HIV-1 luciferase reporter virus. d Monocytes from 6 healthy donors were treated for 24 h with R848 (blue squares) or 
untreated (black dots) and then infected with Vpx-containing HIV-1 luciferase reporter virus bearing a CCR5-tropic transmitted founder envelope 
glycoprotein (HIV1+ HIV1 env) or uninfected (mock). **p ≤ 0.01 In all 4 experiments a–d luciferase activity was measured 72 h post-infection
a b c d
Fig. 4 The block is post-entry at reverse transcription and independent of p21 and RNR. a Monocytes from 3 healthy donors (dot, square, triangle) 
were treated with the indicated R848 concentrations (blue) and infected (VprBlam) or uninfected (−) with two different amounts of Vpr.Blam-
containing HIV-1. The ability of the cells to support virus fusion was measured by flow cytometry. b, c Monocytes from 3 healthy donors (one bar 
per donor) were treated with 10 µM R848 (blue), 100 U/mL IFNα or untreated (–) and 24 h later infected with Vpx-containing HIV-1 reporter virus 
(HIV1 X+). Uninfected (mock) or Nevirapine treated cells and cells infected with HIV-1 reporter virus lacking Vpx (HIV1) served as controls. 40 h 
post-infection, DNA of infected cells was isolated. Early (b) and late (c) HIV-1 reverse transcripts were quantified by RT-qPCR. d Monocytes from two 
donors (one bar per donor) were treated (+, blue) or untreated (−, grey) for 24 h with 10 μM R848. RNA was isolated and p21, RRM2 and IL-1β mRNA 
transcripts were quantified by qRT-PCR and normalized to GAPDH
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luciferase reporter virus. To synchronize the infection, 
the cells were spinnoculated and to prevent degrada-
tion of the viral genomic RNA by reverse transcriptase 
RNaseH, nevirapine was added. At time points shortly 
after infection, the cultures were harvested and the viral 
RNA copy number was quantified by RT qRT-PCR. The 
results showed that over the course of the experiment 
R848 caused a decrease in the number of viral genomic 
RNA copies (Fig. 5a). RT qRT PCR analysis using prim-
ers specific for the 5′ or 3′ ends of the viral RNA showed 
that both ends of the RNA were lost with similar kinetics 
(Fig. 5b, c). The results suggest that the block to reverse 
transcription is associated with degradation of the viral 
RNA and that the degradation occurs at both ends of the 
molecules.
R848 is specific for monocytes and MDM
To determine the cell-type specificity of R848, we tested 
it on activated CD4+ T cells, MDDC and MDM and 
compared its effect to that of IFNα. R848 did not sig-
nificantly protect activated CD4+ T cells or MDDCs 
from infection (Fig.  6a, b) but decreased the infection 
of MDMs 3 to sixfold (Fig. 6c). The effect on MDM was 
significant but less pronounced than the effect on mono-
cytes (compare to Fig. 1). These results demonstrate that 
R848-induced blocked to HIV-1 infection is most pro-
nounced in monocytes.
The block to a single‑round infection is independent 
of type‑I IFN or IL‑1β
R848 could act directly on the target cells or could induce 
the production of soluble factors that provoke cellular 
innate immune defenses by both autocrine and parac-
rine mechanisms. To determine which proinflammatory 
cytokines are induced by R848, we treated monocytes 
for 24 h with increasing concentrations of the drug and 
then measured type-I IFN, IL-1β, IL-6, IL-8, IL-10, IL-12 
and TNFα in the culture medium. The results showed 
that R848 strongly induced type-I IFN as measured in a 
biological assay (Fig.  7a). In addition, R848 induced the 
release of the other cytokines tested starting with as little 
at 0.3–1 μM R848, a concentration similar to that which 
induced the block to monocyte infection (Fig. 7b). Simi-
lar results were obtained for 2 additional donors (Addi-
tional file 5). TNFα, IL-1β, IL-6 and IL-8 were induced by 
more than a 100-fold.
Among the cytokines induced, type-I IFN and IL-1β 
are known inhibitors of HIV-1 replication. To deter-
mine whether type-I IFN played a role in the inhibition, 
we incubated monocytes with a cocktail of antibodies to 
IFNα, IFNβ and the type-I IFN receptor and then treated 
the cells with R848. The following day, we infected the 
cells with Vpx-containing HIV-1 luciferase reporter virus. 
To test the effectiveness of the antibody cocktail, IFNα 
was added to control cultures without R848. The results 
showed that R848 maintained its ability to inhibit infec-
tion in the presence of the antibody cocktail (Fig. 7c). The 
ability of the antibody cocktail to neutralize the antiviral 
effect of  IFNα was confirmed in the control cultures. To 
test for a role for IL-1β in the R848-induced protection, we 
incubated PBMC with increasing concentrations of IL-1β 
for 24 h and then infected the cells with Vpx-containing or 
lacking HIV-1 luciferase reporter virus. IL-1β did not block 
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Fig. 5 The R848-induced block to infection is associated with post-entry destabilization of HIV-1 genomic RNA. Monocytes from healthy donors 
were untreated (−, grey) or treated with 1 μM R848 (+, blue) for 24 h after which the cells were infected with HIV-1 luciferase reporter virus in the 
presence of nevirapine (NVP). The cells were harvested 0.5, 1 and 3 h post-infection and total RNA was prepared. The HIV genomic RNA copy num-
ber was quantified by reverse transcriptase RT-qPCR using primers specific for the luciferase reporter gene (a), the 5′ LTR (b) or the 3′ LTR (c). The 
viral RNA copies were normalized to GAPDH mRNA and the copy number in untreated cells harvested 0.5 h post-infection was set to 1. *p ≤ 0.05, 
**p = <0.001, ***p = 0.0005 and ns not significant
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the antiviral activity of R848 in a single-cycle of infection 
was not mediated by IFNα or IL-1β. This result does not 
rule-out the possibility that the cytokines released affect 
subsequent rounds of virus replication.
R848 treatment of monocytes protects bystander cells
While IL-1β and IFNα are not involved in the block to 
single-cycle infection, it is possible that cytokines released 
in response to R848 protect bystander monocytes as well 
as T cells which themselves do not respond to R848. To 
test for bystander protection, we prepared conditioned 
medium from R848-treated monocytes, transferred it to 
fresh monocyte cultures and then infected the cells with 
Vpx-containing HIV-1 luciferase reporter virus. The 
results showed that the conditioned medium from R848-
treated monocytes protected the monocytes from becom-
ing infected (Fig.  8a). Similar results were obtained in a 
transwell experiment in which monocytes were seeded 
in the bottom compartment and treated with R848 for 2 









































































Fig. 6 R848 does not prevent the infection of CD4+ T cells and MDDC. a Activated CD4+ T cells from 2 healthy donors were treated with 10 µM 
R848 (blue) or 100 U/mL IFNα (light grey) or untreated (dark grey) for 24 h and then infected with Vpx-containing (HIV1 X+) or lacking (HIV1) 
HIV-1 GFP reporter virus or with control supernatant (mock). Infectivity was quantified as percent GFP+ cells 72 h post-infection. b MDDC from 3 
healthy donors (one bar per donor) were incubated with 10 µM R848 (blue) or 100 U/mL IFNα for 24 h or untreated (−). The cells were then infected 
with Vpx-containing (HIV1 X+) HIV1 GFP reporter virus. Uninfected cells (mock) and Nevirapine (NVP) treated cells served as controls. c MDM 
from 3 healthy donors (one bar per donor) were pretreated for 24 h with 10 µM R848 (blue) or untreated and then infected with 3 × 104 (low) or 
3 × 105 (high) cps of Vpx-containing HIV1 luciferase reporter virus. Luciferase activity was measured 72 h post-infection. *p ≤ 0.05, **p ≤ 0.01 and 
***p ≤ 0.001
a b c d
Fig. 7 The block to single-cycle infection induced by R848 is not caused by IFN. a Monocytes from 3 healthy donors (one bar per donor) were 
untreated (mock) or treated with 10 µM R848-treated (blue) and after 24 h, the culture medium was collected and type-I IFN was quantified by bio-
assay. b Monocytes were incubated with different indicated concentrations of R848. After 24 h, the supernatant was collected and proinflammatory 
cytokines were quantified by cytokine bead array. c Monocytes from 2 healthy donors (dot and square) treated with 10 µM R848 (blue) or 100 U/mL 
IFNα with (open symbol) or without (closed symbol) IFN blocking antibody cocktail (±αIFN AB) were infected with Vpx-containing HIV-1 luciferase 
reporter virus. Luciferase activity was measured 72 h post-infection. **p ≤ 0.01 (d) PBMC were treated for 24 h with 100 U/mL IFNα, 10 μM R848 
or 0.1, 1, 10 or 100 ng/mL IL-1β after which the cells were infected with Vpx-containing (HIV1 X+) or lacking (HIV1) HIV-1 luciferase reporter virus. 
Luciferase activity was measured 72 h post-infection
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PBMC were seeded in the top compartment and cells in 
both compartments were infected with Vpx-containing 
HIV-1 luciferase virus. The results showed that the mono-
cytes in the bottom chamber and the PBMC in the top 
chamber were both protected from infection (Fig.  8b, 
c). To determine whether the supernatants would pro-
tect activated T cells, we incubated CD3/CD28-activated 
CD4+ T cells with conditioned medium from drug-
treated or untreated monocytes and infected them with 
HIV-1 GFP reporter virus. The results showed that super-
natant from the R848-treated monocytes blocked infec-
tion of the activated CD4+ T cells (Fig. 8d). Supernatant 
produced by R848-treated activated CD4+ T cells did not 
protect monocytes from infection, demonstrating that the 
results with drug-treated monocytes were not caused by 
carry-over of residual R848 in the cultures (Fig.  8e). To 
determine whether the major inhibitory factor released 
by the monocytes was type-I IFN, we tested whether 
the addition of the IFN blocking antibody cocktail to 
the supernatant derived from R848-treated monocytes 
would neutralize its inhibitory effect. The results showed 
that the antibody cocktail neutralized its antiviral activity 
(Fig. 8f ). We concluded that treatment of monocytes with 
R848 results in dual mechanism of HIV-1 restriction: the 
cell-intrinsic destabilization of the viral RNA, and a cell-
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Fig. 8 IFN released by R848-treated monocytes protects bystander cells from HIV-1 infection. a Monocytes from three healthy donors (one bar 
per donor) were incubated for 24 h with supernatant harvested from untreated (mock supe, grey) or R848-treated monocytes (R848 supe, red). 
Untreated (−) and cells pretreated with 1 µM R848 (R848, blue) served as controls. The cells were then infected with Vpx-containing HIV1 lucif-
erase reporter virus (HIV1 X+) or uninfected (mock). Luciferase activity was measured 72 h post-infection. b, c Monocytes from 3 healthy donors 
treated with R848. The drug was either removed after 2 h (2 h, red) or left on the cells for 24 h (24 h, blue). The treated monocytes were placed in 
the lower compartment of a transwell plate (b) and PBMC were placed in the upper compartment (c). 24 h after R848 treatment, the cells in both 
compartments were infected with Vpx-containing HIV-1 luciferase reporter virus (HIV1 X+). (d) Activated CD4+ T cells from 2 donors were treated 
for 24 h with supernatant from untreated (mock supe), R848-treated monocytes (R848 supe, red) or with 1 μM R848 (R848, blue) and then infected 
with HIV-1 GFP reporter virus, or uninfected (mock). After 72 h, the number of GFP+ cells was determined by flow cytometry. e Monocytes from 3 
healthy donors were treated for 24 h with supernatant from untreated (mock supe, grey) or R848-treated (R848 supe) monocytes (monocyte supe, 
red) or activated CD4+ T cells (CD4+ T cell supe, orange) and then infected with Vpx-containing HIV1 luciferase reporter virus. Controls without 
supernatant pretreatment (−) or treated with R848 (blue) were included. f Monocytes from 3 healthy donors were incubated with increasing 
amounts of supernatant from R848-treated monocytes (R848 supe, red) in the absence (no AB, solid bars) or presence of IFN blocking antibody 
cocktail (αIFN AB, dotted bars). The cells were infected 24 h post-treatment with Vpx-containing HIV-1 luciferase reporter virus
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cells are protected from infection as a result of type-I IFN 
produced by the treated monocytes.
Discussion
We show that the TLR7/8 agonist R848 potently blocks 
HIV-1 replication by acting through two different mecha-
nisms. It induces a post-entry block in monocytes that 
prevents reverse transcription and it causes monocytes 
to secrete type-I IFN that protects bystander T cells. The 
post-entry block results in a major reduction in the num-
ber of viral DNA reverse transcripts and destabilization of 
the viral genomic RNA. The restriction was independent 
of SAMHD1, a restriction factor in myeloid cells that also 
prevents reverse transcription. The R848-induced block 
to infection was active in mouse myeloid cells, which were 
also protected from infection. Because the mouse genome 
encodes a nonfunctional TLR8, this finding suggests that 
TLR7 activation is sufficient to induce the block to HIV-1 
replication [19, 49, 50]. The effect was largely specific to 
monocytes as the drug had no effect on HIV-1 replication 
in activated T cells and a more minor effect on replication 
in MDM. R848 induced monocytes to secrete high levels 
of proinflammatory cytokines, including type-I IFN which 
protected bystander activated T cells from infection. 
Thus, the drug inhibits HIV-1 replication by two path-
ways, one in which a restriction is induced in the target 
monocytes and another in which cytokines are produced 
that protect bystander monocytes and T cells.
R848 treatment of monocytes was associated with a 
significant increase in the post-entry half-life of the viral 
genomic RNA, consistent with a direct inhibition of 
reverse transcription or a prior block to uncoating. The 
decreased stability of the viral genomic RNA could result 
from the induction of a host ribonuclease that attacks the 
reverse transcription complex, or, alternatively, from aber-
rant virion uncoating that subjects the viral genomic RNA 
molecules to attack by host ribonucleases. The effect was 
not the result of HIV-1 reverse transcriptase RNaseH, as 
the addition of nevirapine had no effect on viral genomic 
RNA half-life. In this analysis, we could not rule-out that a 
portion of the viral RNA measured was from virions that 
were either bound to the target cell plasma membrane 
or in endosomes; however, it remains the case that R848 
treatment results in decreased stability of the viral RNA 
suggesting that much of the RNA measured originated 
from virus that had entered the cell.
Although SAMHD1 is known to inhibit HIV-1 reverse 
transcription in monocytes, our findings argue against 
a role for it in the R848-induced block to virus replica-
tion. The block to infection was strongly induced in 
mouse SAMHD1 knock-out BMDCs which are other-
wise highly susceptible to HIV-1. In addition, the R848-
induced block to infection of monocytes was not relieved 
by Vpx, which causes the rapid degradation of SAMHD1. 
R848 did not increase the expression level of SAMHD1 
and did not interfere with the ability of Vpx to degrade 
SAMHD1. Furthermore, the block to infection is not 
consistent with any of the known monocyte-expressed 
restriction factors. MX2 acts post-reverse transcription, 
at nuclear import [51]; IFITMs act at entry [52]; SER-
INC3, SERINC5 [53, 54], REAF [55] and Lv2 [56] do not 
act on VSV-G pseudotyped virus. Moreover, virus pro-
duced in 293T cells is not significantly affected by SER-
INC3 and SERINC5 which are poorly expressed in 293T 
cells. Other known resrtriction factors are also unlikely 
to play a role in the restriction induced by R848. GBP5 
and tetherin act post-integration [57, 58]. While Rhesus 
macaque TRIM5α destabilizes the HIV-1 capsid, human 
TRIM5α has little activity against the virus [59, 60]. In 
addition, while TRIM5α restriction is saturable, the R848 
effect was not.
 Both, TLR7/8 and the cytoplasmic sensors MAVS and 
RIG-I play roles in sensing the RNA of several viruses [17, 
18, 61–63]. While several reports suggest that  TLR7/8 
sense HIV-1 genomic RNA [19, 20], our findings argue 
against such a role in monocytes. TLR7/8 activation by 
R848  induces a strong block to reverse transcription  in 
monocytes. If  HIV-1 virions were to similarly activate 
these TLRs, the infection would be terminated, as is the 
case when the cells are treated with R848. This, how-
ever,  was not the case: Vpx-containing viruses infected 
the monocytes to high levels. R848 prevented HIV-1 
infection when added prior to, or at the same time as the 
virus, demonstrating that the block to infection is acti-
vated rapidly upon TLR7/8 activation and is capable of 
terminating the infection. The ability of HIV-1 to avoid 
activating the TLRs suggest that the virus has evolved a 
strategy to shield its RNA from sensing, as is the case for 
HIV-1 DNA reverse transcripts which are shielded from 
the cytoplasmic double stranded DNA sensor cGAS by 
the viral capsid [64, 65].
A previous study by Wang et  al. [8] showed that 
LPS, R848 and double-stranded RNA induced a post-
entry block to HIV reverse transcription in MDMs but 
not activated T cells. Here, we measured single-cycle 
reporter gene expression rather than released p24 and 
used undifferentiated monocytes rather than MDMs. 
In addition, they found that LPS treatment of MDMs 
induced the secretion of an antiviral factor that was not 
IFNβ. In our experiments, the primary soluble inhibitory 
factor induced by R848-treated monocytes was type-
I IFN. These differences may be due to the use of Vpx-
containing virus that efficiently infects myeloid cells to 
induce high levels of cytokine production. Alternatively, 
monocytes may respond more strongly to TLR activation 
than MDMs.
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Buitendijk et  al. [7] demonstrated that TLR7 and 
TLR8 activation inhibit HIV-1 replication. Treatment of 
MDMs with the TLR7 agonist gardiquimod induced a 
block to infection of co-cultured, activated PBMC and 
treatment of activated PBMC with agonists specific 
for TLRs 3, 7, 8 and 9 blocked HIV-1 replication [10]. 
In both cases, the block was to infection of stimulated 
PBMCs where the major target cells targeted for HIV-1 
infection are activated T cells. We and Wang et  al. [8] 
find that TLR7/8 agonist treatment of activated T cells 
has no effect on HIV-1. Thus, the R848-induced restric-
tion in stimulated PBMC is mediated by a soluble fac-
tor such as type-I IFN released by MDMs, monocytes or 
pDC, while the post-entry block in a single-cycle infec-
tion is due to an intrinsic restriction and not a soluble 
factor.
TLR agonists are under development for clinical use 
in attacking the latent HIV-1 reservoir [66]. Such ago-
nists stimulate transcription of latent proviruses in 
resting T cells without activating the cell [67–71]. Such 
agonists would have the added advantages that they 
induce a potent block to the replication of HIV-1 in 
myeloid cells and induce the production of type-I IFN 
that protects CD4 T cells from infection. In addition, 
the induced production of cytokines such as TNFα 
by monocytes would activate  proviruses in latently 
infected cells. While the   treatment of patients with 
TLR agonists may be accompanied by inflammatory 
responses including lymphopenia, elevated cytokines 
and splenomegaly  as is the case in mice treated 
with R848, agonists under development may be less 
inflammatory.
Conclusion
We show here that R848 induces two independent block 
to HIV-1 replication. The first, is a cell-intrinsic block 
that acts in monocytes to prevent reverse transcrip-
tion, most likely by inducing a novel restriction fac-
tor. The restriction was associated with the post-entry 
destabilization of the HIV-1 genomic RNA, possibly 
caused by the induction of a ribonuclease or by a factor 
that interferes with capsid uncoating. The second, is a 
cell-extrinsic block caused by the R848-induced release 
of proinflammatory cytokines, primarily type-I IFN, 
by monocytes that protects both bystander monocytes 
and CD4+ T cells. The fact that the restriction was not 
induced by HIV-1 infection itself argues that the viral 
RNA is shielded upon uncoating, preventing sensing 
in monocytes by TLR7/8. These findings highlight the 
existence of yet unidentified host restriction factors and 
suggest that the activity identified here may constitute 
“Lv5”.
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Additional files
Additional file 1. R848 blocks Vpx-containing HIV-1 infection from multi-
ple donors. PBMC from healthy donors were pretreated with 10 μM R848 
(blue squares) for 24 h and then infected with HIV1 X+ luciferase reporter 
virus. Infectivity was measured 72 h post infection. The data are from 
independent experiments with 18 different donors (**p = 0.0011).
Additional file 2. R848 is not cytotoxic. a Cell counts of trypan blue 
stained human primary monocytes (2 Donors) 48 h post-treatment with 
the indicated concentration of R848. b Cell viability of monocytes isolated 
from 2 Donors as determined by cell titer assay (Promega) 48 h post-treat-
ment with indicated concentration of R848 (blue). Triton X-100 (TX-100) 
is a control for dead cells. c, d Viability of R848- or IFNα-treated primary 
human monocytes (c) or R848-treated BMDDC from SAMHD1 knock-out 
mice (d) was determined 96 h post treatment by flow cytometry using 
efluor PacBlue viability stain (eBiosciences).
Additional file 3. The R848-induced block is potent. Two additional 
donors, (a) and (b), similar to Fig. 2a are shown. Monocytes were incu-
bated for 24 h with 1 µM (dark blue) or 10 µM (light blue) R848 and then 
infected with increasing amounts of HIV1 X+ luciferase reporter virus (0.1, 
0.3, 1.0 and 3.0 × 106 cps). Uninfected (mock) and cells infected with HIV-1 
luciferase virus lacking Vpx (HIV1) are included as controls.
Additional file 4. R848 does not induce APOBEC3A expression in 
monocytes. Monocytes from 3 healthy donors were treated with 10 μM 
R848, 100 U/mL IFNαor untreated (mock). After 24 h, the cells were lysed 
and the lysates analyzed on an immunoblot probed with anti-APOBEC3A 
(A3A) and anti-tubulin antibody.
Additional file 5. R848 causes the release of pro-inflammatory cytokines. 
Two additional donors, a and b, similar to Fig. 4c are shown. Monocytes 
were incubated with indicated concentrations of R848 and the superna-
tant was collected 24 h post-treatment. Cytokines in the supernatants 
were quantified by cytokine bead array (BD biosciences).
Additional file 6. Recombinant IL-1β does not block HIV infection in 
PBMC. Two additional donors similar to Fig. 4e are shown. PBMC from 2 
healthy donors were treated with 100 U/mL IFNα, 10 μM R848 or 0.1, 1, 
10 or 100 ng/mL IL-1μ for 24 h. The cells were then infected with HIV1 or 
HIV1 X+ luciferase reporter virus and infectivity was measured 72 h post-
infection by luciferase assay.
Page 13 of 14Hofmann et al. Retrovirology  (2016) 13:83 
Received: 24 October 2016   Accepted: 15 November 2016
References
 1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 
2004;4(7):499–511.
 2. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 
2005;17(1):1–14.
 3. Xagorari A, Chlichlia K. Toll-like receptors and viruses: induction of innate 
antiviral immune responses. Open Microbiol J. 2008;2:49–59.
 4. Boivin N, Sergerie Y, Rivest S, Boivin G. Effect of pretreatment with toll-
like receptor agonists in a mouse model of herpes simplex virus type 1 
encephalitis. J Infect Dis. 2008;198(5):664–72.
 5. Sariol CA, Martinez MI, Rivera F, Rodriguez IV, Pantoja P, Abel K, Arana 
T, Giavedoni L, Hodara V, White LJ, et al. Decreased dengue replication 
and an increased anti-viral humoral response with the use of com-
bined Toll-like receptor 3 and 7/8 agonists in macaques. PLoS ONE. 
2011;6(4):e19323.
 6. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter 
D, Wechsler SL, You S, BenMohamed L. A genital tract peptide epitope 
vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T 
cells and protects against herpes simplex virus type 2 challenge. Mucosal 
Immunol. 2009;2(2):129–43.
 7. Buitendijk M, Eszterhas SK, Howell AL. Gardiquimod: a Toll-like receptor-7 
agonist that inhibits HIV type 1 infection of human macrophages and 
activated T cells. AIDS Res Hum Retrovir. 2013;29(6):907–18.
 8. Wang X, Chao W, Saini M, Potash MJ. A common path to innate immunity 
to HIV-1 induced by Toll-like receptor ligands in primary human mac-
rophages. PLoS ONE. 2011;6(8):e24193.
 9. Nian H, Geng WQ, Cui HL, Bao MJ, Zhang ZN, Zhang M, Pan Y, Hu QH, 
Shang H. R-848 triggers the expression of TLR7/8 and suppresses HIV 
replication in monocytes. BMC Infect Dis. 2012;12:5.
 10. Buitendijk M, Eszterhas SK, Howell AL. Toll-like receptor agonists are 
potent inhibitors of human immunodeficiency virus-type 1 replica-
tion in peripheral blood mononuclear cells. AIDS Res Hum Retrovir. 
2014;30(5):457–67.
 11. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal fre-
quency of imiquimod (aldara) 5% cream for the treatment of external 
genital warts in immunocompetent adults: a meta-analysis. Sex Transm 
Dis. 2008;35(4):346–51.
 12. Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S, Slade 
HB, Tyring SK, Warren T, Sacks SL, et al. Topical resiquimod 0.01% gel 
decreases herpes simplex virus type 2 genital shedding: a randomized, 
controlled trial. J Infect Dis. 2007;195(9):1324–31.
 13. Altfeld M, Gale M Jr. Innate immunity against HIV-1 infection. Nat Immu-
nol. 2015;16(6):554–62.
 14. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Bar-
rat FJ, Coffman RL, Staprans SI, Feinberg MB. Divergent TLR7 and TLR9 
signaling and type I interferon production distinguish pathogenic and 
nonpathogenic AIDS virus infections. Nat Med. 2008;14(10):1077–87.
 15. O’Brien M, Manches O, Sabado RL, Baranda SJ, Wang Y, Marie I, Rolnitzky 
L, Markowitz M, Margolis DM, Levy D, et al. Spatiotemporal trafficking 
of HIV in human plasmacytoid dendritic cells defines a persistently 
IFN-alpha-producing and partially matured phenotype. J Clin Investig. 
2011;121(3):1088–101.
 16. O’Brien M, Manches O, Wilen C, Gopal R, Huq R, Wu V, Sunseri N, Bhardwaj 
N. CD4 receptor is a key determinant of divergent HIV-1 sensing by 
plasmacytoid dendritic cells. PLoS Pathog. 2016;12(4):e1005553.
 17. Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW 3rd, Blank-
son JN, Pardoll D, Cox AL. HIV and HCV activate the inflammasome in 
monocytes and macrophages via endosomal Toll-like receptors without 
induction of type 1 interferon. PLoS Pathog. 2014;10(5):e1004082.
 18. Guo H, Gao J, Taxman DJ, Ting JP, Su L. HIV-1 infection induces interleukin-
1beta production via TLR8 protein-dependent and NLRP3 inflammasome 
mechanisms in human monocytes. J Biol Chem. 2014;289(31):21716–26.
 19. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lip-
ford G, Wagner H, Bauer S. Species-specific recognition of single-stranded 
RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526–9.
 20. Meier A, Bagchi A, Sidhu HK, Alter G, Suscovich TJ, Kavanagh DG, Streeck 
H, Brockman MA, LeGall S, Hellman J, et al. Upregulation of PD-L1 
on monocytes and dendritic cells by HIV-1 derived TLR ligands. Aids. 
2008;22(5):655–8.
 21. Simmons RP, Scully EP, Groden EE, Arnold KB, Chang JJ, Lane K, Lifson 
J, Rosenberg E, Lauffenburger DA, Altfeld M. HIV-1 infection induces 
strong production of IP-10 through TLR7/9-dependent pathways. Aids. 
2013;27(16):2505–17.
 22. Nazli A, Kafka JK, Ferreira VH, Anipindi V, Mueller K, Osborne BJ, Dizzell 
S, Chauvin S, Mian MF, Ouellet M, et al. HIV-1 gp120 induces TLR2- and 
TLR4-mediated innate immune activation in human female genital 
epithelium. J Immunol. 2013;191(8):4246–58.
 23. Reuven EM, Ali M, Rotem E, Schwarzer R, Gramatica A, Futerman AH, Shai 
Y. The HIV-1 envelope transmembrane domain binds TLR2 through a 
distinct dimerization motif and inhibits TLR2-mediated responses. PLoS 
Pathog. 2014;10(8):e1004248.
 24. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. 
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 
1986;233(4760):215–9.
 25. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Sriv-
astava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition 
of HIV-1 infection of macrophages mediated by the SAMHD1 protein. 
Nature. 2011;474(7353):658–61.
 26. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral 
E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- 
and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. 
Nature. 2011;474(7353):654–7.
 27. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin 
L, Bloch N, Maudet C, Bertrand M, Gramberg T, et al. SAMHD1 restricts 
the replication of human immunodeficiency virus type 1 by depleting 
the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 
2012;13(6):621.
 28. Brandariz-Nunez A, Valle-Casuso JC, White TE, Laguette N, Benkirane M, 
Brojatsch J, Diaz-Griffero F. Role of SAMHD1 nuclear localization in restric-
tion of HIV-1 and SIVmac. Retrovirology. 2012;9(1):49.
 29. Fujita M, Otsuka M, Miyoshi M, Khamsri B, Nomaguchi M, Adachi A. Vpx 
is critical for reverse transcription of the human immunodeficiency virus 
type 2 genome in macrophages. J Virol. 2008;82(15):7752–6.
 30. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. 
With a little help from a friend: increasing HIV transduction of monocyte-
derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther. 
2006;13(12):991–4.
 31. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, 
Cimarelli A. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a 
proteasome-dependent restriction pathway present in human dendritic 
cells. Retrovirology. 2007;4:2.
 32. Hofmann H, Logue EC, Bloch N, Daddacha W, Polsky SB, Schultz ML, Kim 
B, Landau NR. The Vpx lentiviral accessory protein targets SAMHD1 for 
degradation in the nucleus. J Virol. 2012;86(23):12552–60.
 33. Schule S, Kloke BP, Kaiser JK, Heidmeier S, Panitz S, Wolfrum N, Cichutek 
K, Schweizer M. Restriction of HIV-1 replication in monocytes is abolished 
by Vpx of SIVsmmPBj. PLoS ONE. 2009;4(9):e7098.
 34. Wolfrum N, Muhlebach MD, Schule S, Kaiser JK, Kloke BP, Cichutek K, 
Schweizer M. Impact of viral accessory proteins of SIVsmmPBj on early 
steps of infection of quiescent cells. Virology. 2007;364(2):330–41.
 35. Accola MA, Bukovsky AA, Jones MS, Gottlinger HG. A conserved 
dileucine-containing motif in p6(gag) governs the particle association of 
Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). J 
Virol. 1999;73(12):9992–9.
 36. Sunseri N, O’Brien M, Bhardwaj N, Landau NR. Human immunodefi-
ciency virus type 1 modified to package Simian immunodeficiency 
virus Vpx efficiently infects macrophages and dendritic cells. J Virol. 
2011;85(13):6263–74.
 37. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A 
third-generation lentivirus vector with a conditional packaging system. J 
Virol. 1998;72(11):8463–71.
 38. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, 
Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of 
transmitted and early founder virus envelopes in primary HIV-1 infection. 
Proc Natl Acad Sci USA. 2008;105(21):7552–7.
Page 14 of 14Hofmann et al. Retrovirology  (2016) 13:83 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 39. Hofmann H, Norton TD, Schultz ML, Polsky SB, Sunseri N, Landau NR. 
Inhibition of CUL4A Neddylation causes a reversible block to SAMHD1-
mediated restriction of HIV-1. J Virol. 2013;87(21):11741–50.
 40. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA 
integration in vivo. Nat Med. 2001;7(5):631–4.
 41. Uze G, Di Marco S, Mouchel-Vielh E, Monneron D, Bandu MT, Horis-
berger MA, Dorques A, Lutfalla G, Mogensen KE. Domains of interaction 
between alpha interferon and its receptor components. J Mol Biol. 
1994;243(2):245–57.
 42. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schen-
kova K, Ambiel I, Wabnitz G, Gramberg T, et al. SAMHD1 restricts HIV-1 
infection in resting CD4(+) T cells. Nat Med. 2012;18(11):1682–7.
 43. Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, Yatim 
A, Schwartz O, Laguette N, Benkirane M. SAMHD1 restricts HIV-1 reverse 
transcription in quiescent CD4(+) T-cells. Retrovirology. 2012;9:87.
 44. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-
based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat 
Biotechnol. 2002;20(11):1151–4.
 45. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, Muriaux D, 
Darlix JL, Cimarelli A. APOBEC3A is a specific inhibitor of the early phases 
of HIV-1 infection in myeloid cells. PLoS Pathog. 2011;7(9):e1002221.
 46. Berger A, Munk C, Schweizer M, Cichutek K, Schule S, Flory E. Interaction 
of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family 
member A (APOBEC3A) correlates with efficient lentivirus infection of 
monocytes. J Biol Chem. 2010;285(16):12248–54.
 47. Allouch A, David A, Amie SM, Lahouassa H, Chartier L, Margottin-Goguet 
F, Barre-Sinoussi F, Kim B, Saez-Cirion A, Pancino G. p21-mediated RNR2 
repression restricts HIV-1 replication in macrophages by inhibiting dNTP 
biosynthesis pathway. Proc Natl Acad Sci USA. 2013;110(42):E3997–4006.
 48. Pauls E, Ruiz A, Riveira-Munoz E, Permanyer M, Badia R, Clotet B, Keppler 
OT, Ballana E, Este JA. p21 regulates the HIV-1 restriction factor SAMHD1. 
Proc Natl Acad Sci USA. 2014;111(14):E1322–4.
 49. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi 
T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate 
immune cells via the TLR7 MyD88-dependent signaling pathway. Nat 
Immunol. 2002;3(2):196–200.
 50. Liu J, Xu C, Hsu LC, Luo Y, Xiang R, Chuang TH. A five-amino-acid motif in 
the undefined region of the TLR8 ectodomain is required for species-
specific ligand recognition. Mol Immunol. 2010;47(5):1083–90.
 51. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, Hue S, 
Barclay WS, Schulz R, Malim MH. Human MX2 is an interferon-induced 
post-entry inhibitor of HIV-1 infection. Nature. 2013;502(7472):559–62.
 52. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 
infection. J Virol. 2011;85(5):2126–37.
 53. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, McCauley 
SM, Nowosielska A, Antonarakis SE, Luban J, et al. HIV-1 Nef promotes 
infection by excluding SERINC5 from virion incorporation. Nature. 
2015;526(7572):212–7.
 54. Usami Y, Wu Y, Gottlinger HG. SERINC3 and SERINC5 restrict HIV-1 infectiv-
ity and are counteracted by Nef. Nature. 2015;526(7572):218–23.
 55. Marno KM, Ogunkolade BW, Pade C, Oliveira NM, O’Sullivan E, McKnight 
A. Novel restriction factor RNA-associated early-stage anti-viral factor 
(REAF) inhibits human and simian immunodeficiency viruses. Retrovirol-
ogy. 2014;11:3.
 56. McKnight A, Griffiths DJ, Dittmar M, Clapham P, Thomas E. Characteriza-
tion of a late entry event in the replication cycle of human immunodefi-
ciency virus type 2. J Virol. 2001;75(15):6914–22.
 57. Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Sturzel CM, Mack 
K, Reith E, Engelhart S, Ciuffi A, et al. Guanylate Binding Protein (GBP) 5 Is 
an Interferon-Inducible Inhibitor of HIV-1 Infectivity. Cell Host Microbe. 
2016;19(4):504–14.
 58. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is 
antagonized by HIV-1 Vpu. Nature. 2008;451(7177):425–30.
 59. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The 
cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old 
World monkeys. Nature. 2004;427(6977):848–53.
 60. Stremlau M, Perron M, Welikala S, Sodroski J. Species-specific variation 
in the B30.2(SPRY) domain of TRIM5alpha determines the potency of 
human immunodeficiency virus restriction. J Virol. 2005;79(5):3139–45.
 61. Berg RK, Melchjorsen J, Rintahaka J, Diget E, Soby S, Horan KA, Gorelick 
RJ, Matikainen S, Larsen CS, Ostergaard L, et al. Genomic HIV RNA 
induces innate immune responses through RIG-I-dependent sensing of 
secondary-structured RNA. PLoS ONE. 2012;7(1):e29291.
 62. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of 
MAVS, a mitochondrial antiviral signaling protein that activates NF-
kappaB and IRF 3. Cell. 2005;122(5):669–82.
 63. Solis M, Nakhaei P, Jalalirad M, Lacoste J, Douville R, Arguello M, Zhao T, 
Laughrea M, Wainberg MA, Hiscott J. RIG-I-mediated antiviral signaling 
is inhibited in HIV-1 infection by a protease-mediated sequestration of 
RIG-I. J Virol. 2011;85(3):1224–36.
 64. Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, El Marjou A, 
Lacabaratz C, Lelievre JD, Manel N. The capsids of HIV-1 and HIV-2 deter-
mine immune detection of the viral cDNA by the innate sensor cGAS in 
dendritic cells. Immunity. 2013;39(6):1132–42.
 65. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, Jacques 
DA, Selwood DL, James LC, Noursadeghi M, et al. HIV-1 evades innate 
immune recognition through specific cofactor recruitment. Nature. 
2013;503(7476):402–5.
 66. Offersen R, Nissen SK, Rasmussen TA, Ostergaard L, Denton PW, Sogaard 
OS, Tolstrup M. A novel Toll-like receptor 9 agonist, MGN1703, enhances 
HIV-1 transcription and NK cell-mediated inhibition of HIV-1-infected 
autologous CD4+ T cells. J Virol. 2016;90(9):4441–53.
 67. Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, 
Margolis DM, Planelles V, Bosque A. Reactivation of latent HIV-1 in central 
memory CD4(+) T cells through TLR-1/2 stimulation. Retrovirology. 
2013;10:119.
 68. Scheller C, Ullrich A, McPherson K, Hefele B, Knoferle J, Lamla S, Olbrich 
AR, Stocker H, Arasteh K, ter Meulen V, et al. CpG oligodeoxynucleotides 
activate HIV replication in latently infected human T cells. J Biol Chem. 
2004;279(21):21897–902.
 69. Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts 
opposing effects in acute versus latent HIV infection. J Immunol. 
2006;176(5):2888–95.
 70. Schlaepfer E, Speck RF. TLR8 activates HIV from latently infected cells 
of myeloid-monocytic origin directly via the MAPK pathway and from 
latently infected CD4+ T cells indirectly via TNF-alpha. J Immunol. 
2011;186(7):4314–24.
 71. Thibault S, Imbeault M, Tardif MR, Tremblay MJ. TLR5 stimulation is 
sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid 
cells and activate virus gene expression in central memory CD4+ T cells. 
Virology. 2009;389(1–2):20–5.
